Zobrazeno 1 - 10
of 154
pro vyhledávání: '"Luis F López-Cortés"'
Autor:
Luis F López-Cortés, Manuel A Castaño, Miguel A López-Ruz, María J Rios-Villegas, José Hernández-Quero, Dolores Merino, Patricia Jiménez-Aguilar, Manuel Marquez-Solero, Alberto Terrón-Pernía, Francisco Tellez-Pérez, Pompeyo Viciana, Francisco Orihuela-Cañadas, Zaira Palacios-Baena, David Vinuesa-Garcia, Jose M Fajardo-Pico, Alberto Romero-Palacios, Guillermo Ojeda-Burgos, Juan Pasquau-Liaño
Publikováno v:
PLoS ONE, Vol 11, Iss 2, p e0148924 (2016)
BACKGROUND AND OBJECTIVE:Significant controversy still exists about ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv) as a simplification strategy that is used up to now to treat patients that have not experienced previous virological failu
Externí odkaz:
https://doaj.org/article/68978ecd16e8457abeccfd431b980b4a
Autor:
Juan Macías, Luis F López-Cortés, Francisco Téllez, Eva Recio, Guillermo Ojeda-Burgos, Maria José Ríos, Antonio Rivero-Juárez, Marcial Delgado, Rivas-Jeremías, Juan A Pineda
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0143492 (2015)
Nitazoxanide (NTZ) plus pegylated interferon and ribavirin (Peg-IFN/RBV) improved the sustained virological response (SVR) achieved with Peg-IFN/RBV in hepatitis C virus genotype 4 (HCV-4)-monoinfected patients. There are no data currently on the eff
Externí odkaz:
https://doaj.org/article/a117626c031d44a1b93460456223b611
Autor:
Karin Neukam, Daniela I Munteanu, Antonio Rivero-Juárez, Thomas Lutz, Jan Fehr, Mattias Mandorfer, Sanjay Bhagani, Luis F López-Cortés, Annette Haberl, Marcel Stoeckle, Manuel Márquez, Stefan Scholten, Ignacio de Los Santos-Gil, Stefan Mauss, Antonio Rivero, Antonio Collado, Marcial Delgado, Juergen K Rockstroh, Juan A Pineda
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0125080 (2015)
Clinical trials of therapy against chronic hepatitis C virus (HCV) infection including boceprevir (BOC) or telaprevir (TVR) plus pegylated interferon and ribavirin (PR) have reported considerably higher response rates than those achieved with PR alon
Externí odkaz:
https://doaj.org/article/e26652369a0c4196ad0dcb9fb3386485
Autor:
Sara Corchado, Luis F López-Cortés, Antonio Rivero-Juárez, Almudena Torres-Cornejo, Antonio Rivero, Mercedes Márquez-Coello, José-Antonio Girón-González
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e101760 (2014)
OBJECTIVE: To establish the role of liver fibrosis as a predictive tool of response to pegylated interferon alpha (Peg-IFN) and ribavirin (RBV) treatment in human immunodeficiency (HIV)/hepatitis C virus (HCV) coinfected patients, in addition to reco
Externí odkaz:
https://doaj.org/article/c21f7243c77a468797d45c903ccfd2dc
Autor:
Antonio Rivero-Juarez, Luis F López-Cortés, Angela Camacho, Almudena Torres-Cornejo, Ana Gordon, Rosa Ruiz-Valderas, Julian Torre-Cisneros, Juan A Pineda, Pompeyo Viciana, Antonio Rivero
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e99468 (2014)
Optimizing HCV genotype 1 therapy in terms of response prediction and tailoring treatment is undoubtedly the cornerstone of treating HIV co-infected patients in clinical practice. Accordingly, our aim was to analyze the predictive value of HCV viral
Externí odkaz:
https://doaj.org/article/a7e417e1748149ba8f715d75ea3d781a
Autor:
Luis F López-Cortés, Pompeyo Viciana, José A Girón-González, Alberto Romero-Palacios, Manuel Márquez-Solero, Maria A Martinez-Perez, Miguel A López-Ruz, Javier de la Torre-Lima, Francisco Téllez-Pérez, Marcial Delgado-Fernández, Milagros Garcia-Lázaro, Fernando Lozano, Mohamed O Mohamed-Balghata, Sociedad Andaluza de Enfermedades Infecciosas
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e97262 (2014)
Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase inhibi
Externí odkaz:
https://doaj.org/article/da0a60b884584da2918b7b6b43925c2a
Autor:
Luis F López-Cortés, Rosa Ruiz-Valderas, Luis Jimenez-Jimenez, María F González-Escribano, Almudena Torres-Cornejo, Rosario Mata, Antonio Rivero, Juan A Pineda, Manuel Marquez-Solero, Pompeyo Viciana, Grupo para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e28115 (2012)
BACKGROUND:Data on which to base definitive recommendations on the doses and duration of therapy for genotype 3 HCV/HIV-coinfected patients are scarce. We evaluated the efficacy of a lower peginterferon-α 2a dose and a shorter duration of therapy th
Externí odkaz:
https://doaj.org/article/16ba3d97550b4e0f85774a45f664c0a4
Autor:
Esperanza Muñoz-Muela, María Trujillo-Rodríguez, Ana Serna-Gallego, Abraham Saborido-Alconchel, Ezequiel Ruiz-Mateos, Luis F. López-Cortés, Alicia Gutiérrez-Valencia
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 168, Iss , Pp 115750- (2023)
Background: Dual therapy (DT) has shown comparable results to triple therapy (TT) in efficacy and other immunological aspects. However, there are still some concerns about DT, including several immunological features. Therefore, we evaluated whether
Externí odkaz:
https://doaj.org/article/0b0bafcb703f4e2982f42831a3ea9e0e
Autor:
Luis F. López-Cortés, Abraham Saborido-Alconchel, María Trujillo-Rodríguez, Ana Serna-Gallego, Silvia Llaves-Flores, Esperanza Muñoz-Muela, María Jesús Pérez-Santos, Carmen Lozano, Marta Mejias-Trueba, Cristina Roca, Nuria Espinosa, Alicia Gutiérrez-Valencia
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundData on SARS-CoV-2 mRNA vaccine immunogenicity in people living with human immunodeficiency virus (PLWH) and discordant immune response (DIR) are currently limited. Therefore, we compare the immunogenicity of these vaccines in DIR and immun
Externí odkaz:
https://doaj.org/article/e04a3dcba2804c148a22db3db5633951
Autor:
Karin Neukam, Cristina Roca, Pompeyo Viciana, Luis F. López-Cortés, Yusnelkis Milanés Guisado, Nuria Espinosa, María Fontillón, Ana Domínguez Castaño, Cesar Sotomayor
Publikováno v:
Diseases of the Colon & Rectum. 65:28-39
Anal squamous cell carcinoma is rare, in general, but considerably higher in HIV-infected men who have sex with men. There is no consensus on the screening of at-risk populations.This study aimed to determine the incidence rates of anal squamous cell